Results 51 to 60 of about 10,308 (152)

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source

XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia

Iranian Journal of Blood and Cancer, 2016
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML).
Abolghasem Allahyari, Foroogh Salehi, Mostafa Kaboli, Masoud Sadeghi   +3 more
doaj  

Diabetic Atrial Cardiomyopathy: Pathogenesis, Diagnosis, Management, AI‐Driven Diagnosis, and Risk Prediction

Journal of Diabetes Research, Volume 2026, Issue 1, 2026.
Background Diabetic atrial cardiomyopathy, a component of diabetic cardiomyopathy, is increasingly recognized. However, atrial‐focused mechanistic and clinical frameworks remain less developed than ventricular paradigms. Main Body This review synthesizes the pathogenesis of diabetic atrial cardiomyopathy from conventional, multiomics, and translational
Helin Yang, Kexiao Yu, Bing Liang, Zhipeng Tao   +3 more
wiley   +1 more source

High Shear Stress‐Induced Endothelial Piezo1 Downregulation Promotes Intracranial Aneurysm Formation via the PDGF‐BB/PDGFRβ Paracrine Signaling Pathway

CNS Neuroscience &Therapeutics, Volume 31, Issue 12, December 2025.
HSS downregulates Piezo1 expression in ECs, which subsequently enhances PDGF‐BB expression through the YAP/β‐catenin signaling pathway. The elevated PDGF‐BB facilitates phenotypic transition of VSMCs via PDGFRβ binding, ultimately contributing to IA formation.
Zhiwen Lu, Sisi Li, Fengfeng Xu, Haishuang Tang, Shijie Zhu, Chuanchuan Wang, Xiaohua Yang, Qinghai Huang   +7 more
wiley   +1 more source

Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib

Indian Journal of Pathology and Microbiology, 2013
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj   +1 more source

The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Advances in Hematology, 2010
Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec)
K. G. Koffi, D. C. Nanho, E. N'dathz, P. Kouehion, R. Dissieka, A. Attia, K. Mozard, A. Tolo, K. Boidy, N. Meité, R. Ayemou, M. Sekongo, N. Tea, I. Sanogo   +13 more
doaj   +1 more source

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report

Revista Colombiana de Cardiología, 2008
La cardiotoxicidad por medicamentos es un evento cada vez más frecuente en la práctica clínica diaria. Inhibidores de la proteína de fusión Brc/Abl como el imatinib mesilato, son una nueva herramienta para el tratamiento de algunas neoplasias ...
Clara Saldarriaga, Jairo A Rendón, Juan M Senior   +2 more
doaj  

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?

Turkish Journal of Hematology, 2016
INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM
Olga Meltem Akay, Fezan Şahin Mutlu, Zafer Gülbaş   +2 more
doaj   +1 more source

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

Maxillofacial Plastic and Reconstructive Surgery, 2017
Background Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML).
Gian Paolo Bombeccari, Umberto Garagiola, Francesco Pallotti, Margherita Rossi, Massimo Porrini, Aldo Bruno Giannì, Francesco Spadari   +6 more
doaj   +1 more source

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

International Journal of Nanomedicine, 2015
Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological ...
Marslin G, Revina AM, Khandelwal VKM, Balakumar K, Prakash J, Franklin G, Sheeba CJ   +6 more
doaj